A phase III, multi-center, placebo-controlled study to evaluate the clinical efficacy and safety of inductions and maintenance therapy with abatacept in subjects with active ulcerative colitis (UC) who have had an inadequate clinical response and/or intolerance to medical therapy

This study will test the efficacy and safety of the study drug compared to placebo. This study involves three phases: induction, maintenance and extension. Participants will be randomized to receive either the active study drug or placebo for the induction and maintenance phases. In the extension phase, participants will receive active treatment.  The induction period may last for up to 85 days. The maintenance period may last for up to 365 days (one year). The extension phase may last until the study drug is marketed for ulcerative colitis.

You may be eligible to participate in the study if you have moderate to severe ulcerative colitis and have  failed at least one of the following treatments:

• ASA
• Corticosteroid
• Immunosuppressant
• Anti-TNF

This is a partial list of eligibility requirements. For further information or to determine if you are eligible to participate, please call the number provided. If you choose to inquire via e-mail, please refer to the title of the study in your message.